Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00010413|
Recruitment Status : Completed
First Posted : February 2, 2001
Last Update Posted : October 2, 2008
I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
|Condition or disease||Intervention/treatment||Phase|
|Pemphigus||Drug: cyclophosphamide Drug: filgrastim||Phase 2|
PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.
Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for a year, and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Study Start Date :||April 1999|
|Primary Completion Date :||August 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00010413
|United States, Maryland|
|Johns Hopkins University School of Medicine|
|Baltimore, Maryland, United States, 21205|
|Study Chair:||Grant J. Anhalt||Johns Hopkins University|